- Home
- NRIX vs LQDT Comparison
NRIX vs LQDT Comparison
Compare NRIX & LQDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- LQDT
- Stock Information
- Founded
- NRIX 2009
- LQDT 1999
- Country
- NRIX United States
- LQDT United States
- Employees
- NRIX N/A
- LQDT N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- LQDT Catalog/Specialty Distribution
- Sector
- NRIX Health Care
- LQDT Consumer Discretionary
- Exchange
- NRIX Nasdaq
- LQDT Nasdaq
- Market Cap
- NRIX 1.1B
- LQDT 1.0B
- IPO Year
- NRIX 2020
- LQDT 2006
- Fundamental
- Price
- NRIX $11.88
- LQDT $31.01
- Analyst Decision
- NRIX Strong Buy
- LQDT Strong Buy
- Analyst Count
- NRIX 17
- LQDT 2
- Target Price
- NRIX $30.82
- LQDT $38.50
- AVG Volume (30 Days)
- NRIX 879.4K
- LQDT 311.6K
- Earning Date
- NRIX 04-14-2025
- LQDT 05-08-2025
- Dividend Yield
- NRIX N/A
- LQDT N/A
- EPS Growth
- NRIX N/A
- LQDT 27.06
- EPS
- NRIX N/A
- LQDT 0.75
- Revenue
- NRIX $54,549,000.00
- LQDT $414,324,000.00
- Revenue This Year
- NRIX N/A
- LQDT $36.53
- Revenue Next Year
- NRIX $3.20
- LQDT $9.50
- P/E Ratio
- NRIX N/A
- LQDT $41.50
- Revenue Growth
- NRIX N/A
- LQDT 32.16
- 52 Week Low
- NRIX $11.38
- LQDT $16.79
- 52 Week High
- NRIX $29.56
- LQDT $39.72
- Technical
- Relative Strength Index (RSI)
- NRIX 29.28
- LQDT 45.53
- Support Level
- NRIX $12.20
- LQDT $30.49
- Resistance Level
- NRIX $13.10
- LQDT $33.21
- Average True Range (ATR)
- NRIX 0.77
- LQDT 1.05
- MACD
- NRIX -0.01
- LQDT 0.20
- Stochastic Oscillator
- NRIX 14.33
- LQDT 48.60
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About LQDT Liquidity Services Inc.
Liquidity Services Inc is an online auction marketplace. It manages and sells inventory and equipment for business and government clients by operating a network of e-commerce marketplaces that enable buyers and sellers to transact in an efficient, automated environment offering across different product categories. The company has four reportable segments: GovDeals, Capital Assets Group (CAG), Retail Supply Chain Group (RSCG), and Machinio. It generates majority of its revenue from Retail Supply Chain Group (RSCG) segment which consists of marketplaces that enable corporations located in the United States and Canada to sell excess, returned, and overstocked consumer goods. Geographically, a substantial portion the company's revenue is generated from its business in United States.